HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: For instance, the HDAC inhibitor Zolinza (Suberoylanilide hydroxamic acid or SAHA), approved for the treatment of cutaneous T cell lymphoma (CTCL) patients, is an effective inhibitor of HDAC I, II, and IV [102].